Company Directory

Small molecule drug discovery targeting rare genetic diseases and oncology

Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic fibrosis, Duchenne muscular dystrophy, and epidermolysis bullosa. The company previously discovered and out-licensed two BET inhibitor programmes to VYNE Therapeutics, which are advancing in clinical trials for immuno-inflammatory conditions.

CRO specialising in oncology, inflammation and respiratory disease models

Axis Bioservices is a preclinical contract research organisation providing bespoke in vitro and in vivo study services for pharmaceutical, biotechnology and academic clients. Specialist capabilities span oncology tumour models, inflammatory disease models including rheumatoid arthritis and pulmonary fibrosis, and respiratory disease models for conditions such as COPD and asthma. Services cover efficacy, mechanistic, and pharmacokinetic studies tailored to individual drug development programmes.

UK affiliate of global family-owned biopharmaceutical company

Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates across therapeutic areas including respiratory disease, cardiovascular disease, oncology, immunology, and metabolic disorders. It is a member of the ABPI and one of the largest pharmaceutical employers in Berkshire.

Human biospecimen and disease-state plasma supplier

Logical Biological is a UK supplier of human biological materials including disease-state and normal-donor serum, plasma, swabs, tissues, PBMCs, and biofluids to IVD manufacturers and life science researchers worldwide. The company sources specimens through a global network of donor centres and blood banks across five continents, and provides customised materials including bulk engineered disease-state plasma, with capabilities in protein purification and sample processing. Customers include diagnostic test developers and IVD control manufacturers.

In vitro biology CRO for immunology and oncology drug discovery

BioMedha is a pre-clinical contract research organisation specialising in in vitro biology for early-stage drug discovery. The company provides assay development, target validation, compound screening, and mechanism of action studies across immunology, oncology, immuno-oncology, and inflammation therapeutic areas. Capabilities include whole blood and immune cell functional assays, flow cytometry, cytokine and Luminex multiplex assays, cell imaging, and discovery toxicology. BioMedha is an HTA authorised establishment with an on-site blood donor panel.

AI-driven neural data platform for bioelectronic medicine

BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation therapies and neural digital therapeutics. BIOS serves pharmaceutical and medical device partners, academic research institutions, and NHS clinical programmes targeting cardiovascular, neurological, and autoimmune conditions.

Immunometabolism-targeting small molecules for autoimmune disease

Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics that modulate immune cell metabolism to achieve disease remission in autoimmune and inflammatory conditions. The company's approach targets novel metabolic enzymes within immune cells, with lead programmes in atopic dermatitis and psoriatic arthritis. Founded by researchers in immunology and metabolism, Sitryx has attracted investment from major pharmaceutical companies and specialist life science funds.

Next-generation kinase inhibitors for autoimmune disease and cancer

Sareum is a clinical-stage biotechnology company developing small molecule kinase inhibitors for the treatment of autoimmune diseases and cancer. The company's pipeline centres on dual TYK2/JAK1 inhibition, with programmes targeting psoriasis, rheumatoid arthritis, lupus, inflammatory bowel disease and cancer immunotherapy, alongside a Chk1 inhibitor programme in oncology. Programmes are advanced to early clinical stage before out-licensing to pharmaceutical and biotechnology partners. Sareum is listed on the AIM market of the London Stock Exchange.

NLRP3 inflammasome inhibitors for chronic inflammatory disease

NodThera is a clinical-stage biotechnology company developing potent and selective small molecule inhibitors of the NLRP3 inflammasome for diseases driven by chronic inflammation. Its lead asset, NT-0796, is a brain-penetrant oral inhibitor in Phase Ib/IIa clinical trials for Parkinson's disease and obesity-related cardiovascular conditions. The NLRP3 inflammasome is implicated in a broad range of inflammatory and neurodegenerative diseases, and NodThera's pipeline targets multiple indications across this biology.

Immunometabolism drugs for autoimmune and inflammatory diseases

Istesso is a drug discovery and development company working in immunometabolism, developing oral small molecule therapies that reprogram cellular metabolism to treat autoimmune and inflammatory conditions. Its lead candidate is a first-in-class metabolic reprogramming agent for rheumatoid arthritis with a dual mechanism targeting both inflammation and bone degradation, and has completed Phase 2a trials. The pipeline extends to multiple sclerosis and pulmonary fibrosis. Istesso holds a licence agreement with Janssen Biotech.

GPR35 inhibitors for gastrointestinal cancer and inflammatory bowel disease

ThirtyFiveBio is a drug discovery company developing first-in-class small molecule inhibitors of GPR35, a genetically validated G protein-coupled receptor implicated in gastrointestinal disease. The company's approach targets GPR35 antagonism to prevent epithelial cell damage and dysfunction in the gut wall, addressing underlying disease biology rather than inflammation directly. Lead molecules are advancing through IND-enabling studies targeting ulcerative colitis and colorectal cancer.

Tissue-level disease platform for endometriosis drug discovery

Cyclana Bio is a drug discovery company developing tissue-level therapeutics for endometriosis and women's health conditions. The company builds whole-tissue disease models using menstrual fluid collected through an observational clinical trial, combined with AI-driven multi-omic data integration to identify novel targets. Its research focuses on the role of extracellular matrix dysregulation in driving inflammation and tissue dysfunction. Cyclana Bio's platform is designed to extend beyond endometriosis into other chronic inflammatory diseases sharing similar tissue-level mechanisms.